OPDIVO (nivolumab), anti-PD1 antibody

High clinical benefit and minor clinical added value over docetaxel, cetuximab or methotrexate monotherapy in the treatment of advanced stage squamous cell carcinoma of the upper aerodigestive tract, progressing either during or after platinum salt-based chemotherapy.

• OPDIVO has been granted marketing authorisation for the treatment of adults in monotherapy for advanced upper aerodigestive tract cancer, progressing during or after platinum salt-based chemotherapy.

• Its superiority over docetaxel, cetuximab or methotrexate monotherapy has been established.

• It is a second-line treatment, after failure of previous platinum salt-based treatment.

-